Meta‐analysis of randomized controlled trials for the development of the International Federation for Surgery of Obesity and Metabolic Disorders‐European Chapter (IFSO‐EC) guidelines on multimodal strategies for the surgical treatment of obesity
Authors' conclusion
MBS combined with non-surgical approaches appears more effective than MBS alone in reducing BMI. Further RCTs on combined therapies to MBS for severe obesity are needed to enhance the tailoring of treatment for severe obesity.
Study context
- Population
- Patients undergoing different metabolic bariatric surgery (MBS) procedures for obesity; Randomized, controlled trials (RCTs) with duration of at least 6 months25 RCTs
- Comparison
- MBS add-on to other anti-obesity strategies vs MBS alone
- Outcome
- BMI at the end-point
Pooled result
As reported in the abstract
- MBS + add-on vs MBS alone: P = 0.040
Further pooled results
%EWL, %total weight loss (TWL) and TBWL with liraglutide add-on to MBS
- Liraglutide added to MBS associated with greater %EWL, but not %TWL and TBWL
- P = 0.008
HbA1c at end-point with liraglutide add-on to MBS
- Significant reduction in favour of liraglutide as add-on to MBS
- P = 0.007
- 3 trials
Mortality
- There was no mortality
Original publication
Meta‐analysis of randomized controlled trials for the development of the International Federation for Surgery of Obesity and Metabolic Disorders‐European Chapter (IFSO‐EC) guidelines on multimodal strategies for the surgical treatment of obesity. Diabetes Obes Metab. Published 8 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →